+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

  • PDF Icon

    Report

  • 156 Pages
  • May 2022
  • Region: Global
  • GlobalData
  • ID: 5614881
Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Summary


The publisher's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update` provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy


The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Dry Powder Inhaler Devices Overview
3 Products under Development
3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory
3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials
4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
5 Dry Powder Inhaler Devices Companies and Product Overview
5.1 Acorda Therapeutics Inc Company Overview
5.2 Adamis Pharmaceuticals Corp Company Overview
5.3 Advent Pharmaceuticals Pty Ltd Company Overview
5.4 Aespira Ltd. Company Overview
5.5 AKELA Pharma Inc. (Inactive) Company Overview
5.6 AstraZeneca Plc Company Overview
5.7 Bayer AG Company Overview
5.8 Cambridge Healthcare Innovations Ltd Company Overview
5.9 Circassia Group Plc Company Overview
5.10 Creare LLC Company Overview
5.11 Eli Lilly and Co Company Overview
5.12 GlaxoSmithKline Plc Company Overview
5.13 Glenmark Pharmaceuticals Ltd Company Overview
5.14 Hovione Technology Ltd Company Overview
5.15 Iconovo AB Company Overview
5.16 Lupin Pharmaceuticals Inc Company Overview
5.17 MannKind Corp Company Overview
5.18 Monash University Company Overview
5.19 Nektar Therapeutics Company Overview
5.20 Ology Bioservices Inc Company Overview
5.21 OPKO Health Inc Company Overview
5.22 OtiTopic Inc Company Overview
5.23 Phargentis SA Company Overview
5.24 Pharmaxis Ltd Company Overview
5.25 Quench Medical Inc Company Overview
5.26 Respira Therapeutics Inc Company Overview
5.27 Respirent Pharmaceuticals Co Ltd Company Overview
5.28 Sandoz International GmbH Company Overview
5.29 Sheffield Hallam University Company Overview
5.30 Shin Nippon Biomedical Laboratories Ltd Company Overview
5.31 Spyryx Biosciences Inc (Inactive) Company Overview
5.32 Sun Pharma Advanced Research Company Ltd Company Overview
5.33 United Therapeutics Corp Company Overview
5.34 University of Kansas Company Overview
5.35 University of Sydney Company Overview
5.36 University of Texas Medical Branch at Galveston Company Overview
5.37 Vectura Group Plc Company Overview
5.38 Verona Pharma Plc Company Overview
5.39 Virginia Commonwealth University Company Overview
6 Dry Powder Inhaler Devices- Recent Developments
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Dry Powder Inhaler Devices - Pipeline Products by Territory
  • Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • Dry Powder Inhaler Devices - Ongoing Clinical Trials
  • Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
  • Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Glossary

List of Figures
  • Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Dry Powder Inhaler Devices - Pipeline Products by Territory
  • Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • Dry Powder Inhaler Devices - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acorda Therapeutics Inc
  • Adamis Pharmaceuticals Corp
  • Advent Pharmaceuticals Pty Ltd
  • Aespira Ltd.
  • AKELA Pharma Inc. (Inactive)
  • AstraZeneca Plc
  • Bayer AG
  • Cambridge Healthcare Innovations Ltd
  • Circassia Group Plc
  • Creare LLC
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Hovione Technology Ltd
  • Iconovo AB
  • Lupin Pharmaceuticals Inc
  • MannKind Corp
  • Monash University
  • Nektar Therapeutics
  • Ology Bioservices Inc
  • OPKO Health Inc
  • OtiTopic Inc
  • Phargentis SA
  • Pharmaxis Ltd
  • Quench Medical Inc
  • Respira Therapeutics Inc
  • Respirent Pharmaceuticals Co Ltd
  • Sandoz International GmbH
  • Sheffield Hallam University
  • Shin Nippon Biomedical Laboratories Ltd
  • Spyryx Biosciences Inc (Inactive)
  • Sun Pharma Advanced Research Company Ltd
  • United Therapeutics Corp
  • University of Kansas
  • University of Sydney
  • University of Texas Medical Branch at Galveston
  • Vectura Group Plc
  • Verona Pharma Plc
  • Virginia Commonwealth University